Systemic light-chain (AL) amyloidosis is an uncommon hematologic plasma cell dyscrasia that is becoming increasingly recognized. Therapeutic agents used in AL amyloidosis overlap with those used in multiple myeloma; however, differences in disease features change treatment efficacy and tolerance. Pharmacists must be cognizant of these distinctions. Herein, this review article provides an up-to-date guide to treatment considerations for systemic AL amyloidosis in both the front-line and relapsed settings.
Data sources: A comprehensive literature search was performed using the PubMed/Medline database for articles published through (June 2020) regarding treatments for AL amyloidosis. Search criteria included therapies that are FDA approved for multiple myeloma, as well as investigational agents. This review of chemotherapeutic agents reflects the current clinical practice guidelines endorsed by NCCN along with commentary based on the experience of pharmacists from a tertiary-referral center treating many patients with AL amyloidosis. Data consists of randomized controlled trials, observational cohorts, case reports, and ongoing clinical trials.
Data summary: Frontline options discussed here include high-dose melphalan with autologous stem cell transplantation and bortezomib-based regimens. Regarding the relapsed setting, supporting data are compiled and summarized for: bortezomib, ixazomib, carfilzomib, lenalidomide, pomalidomide, daratumumab, elotuzumab, isatuximab, venetoclax, NEOD001, and melflufen.
Conclusions
The treatment platform for AL amyloidosis is expanding with novel agents traditionally used in multiple myeloma being adopted and modified for use in AL amyloidosis. The pharmacist’s familiarity with the clinical evidence base for these agents and how they fit into standard protocols for AL amyloidosis is critical as dosing and monitoring recommendations are unique from multiple myeloma.
BensonMDBuxbaumJNEisenbergDS, et al.
Amyloid nomenclature 2018: recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid2018;
25: 215–219.
3.
StaronAConnorsLHRubergFLMendelsonLM, et al.
A new era of amyloidosis: the trends at a major US referral Centre. Amyloid2019;
26: 192–196.
4.
QuockTPYanTChangE, et al.
Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv2018;
2: 1046–1053.
5.
KyleRALinosABeardCM, et al.
Incidence and natural history of primary systemic amyloidosis in Olmsted county, Minnesota, 1950 through 1989. Blood1992;
79: 1817–1822.
6.
ShimazakiCHataHIidaS, et al.
Nationwide survey of 741 patients with systemic amyloid light-chain amyloidosis in Japan. Intern Med2018;
57: 181–187.
7.
KyleRALarsonDRTherneauTM, et al.
Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med2018;
378: 241–249.
8.
da Silva FilhoMIForstiAWeinholdN, et al.
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma. Leukemia2017;
31: 1735–1742.
9.
BochtlerTMerzMHielscherT, et al.
Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Adv2018;
2: 2607–2618.
10.
KakuMBerkJL.Neuropathy associated with systemic amyloidosis. Semin Neurol2019;
39: 578–588.
11.
DispenzieriAGertzMAKyleRA, et al.
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. JCO2004;
22: 3751–3757.
12.
KumarSDispenzieriALacyMQ, et al.
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol2012;
30: 989–995.
13.
LillenessBRubergFLMussinelliR, et al.
Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood2019;
133: 215–223.
14.
PalladiniGHegenbartUMilaniP, et al.
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood2014;
124: 2325–2332.
15.
GertzMAComenzoRFalkRH, et al.
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, tours, France, 18–22 April 2004. Am J Hematol2005;
79: 319–328.
16.
ComenzoRLReeceDPalladiniG, et al.
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia2012;
26: 2317–2325.
17.
PalladiniGDispenzieriAGertzMA, et al.
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol2012;
30: 4541–4549.
18.
KaufmanGPDispenzieriAGertzMA, et al.
Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol2015;
90: 181–186.
19.
DispenzieriABuadiFKumarSK, et al.
Treatment of immunoglobulin light chain amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement. Mayo Clin Proc2015;
90: 1054–1081.
20.
SkinnerMSanchorawalaVSeldinDC, et al.
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med2004;
140: 85–93.
21.
GertzMALacyMQDispenzieriA, et al.
Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant2013;
48: 557–561.
22.
SanchorawalaV.High-Dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Acta Haematol2020;
143: 381–387.
23.
GirniusSSeldinDCMeier-EwertHK, et al.
Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement. Bone Marrow Transplant2014;
49: 434–439.
24.
SanchorawalaVBrauneisDSheltonAC, et al.
Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: Results of a prospective clinical trial. Biol Blood Marrow Transplant2015;
21: 1445–1451.
25.
HuangXWangQChenW, et al.
Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. BMC Med2014;
12: 2.
26.
MinnemaMCNasserinejadKHazenbergB, et al.
Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. Haematologica2019;
104: 2274–2282.
27.
LillebyKGarciaPGooleyT, et al.
A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant2006;
37: 1031–1035.
28.
SanchorawalaVSunFQuillenK, et al.
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood2015;
126: 2345–2347.
29.
SeldinDCAndersonJJSanchorawalaV, et al.
Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood2004;
104: 1888–1893.
MoreauPPylypenkoHGrosickiS, et al.
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol2011;
12: 431–440.
32.
VennerCPLaneTFoardD, et al.
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood2012;
119: 4387–4390.
33.
MikhaelJRSchusterSRJimenez-ZepedaVH, et al.
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood2012;
119: 4391–4394.
34.
ManwaniRCohenOSharpleyF, et al.
A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood2019;
134: 2271–2280.
35.
PalladiniGPerfettiVObiciL, et al.
Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood2004;
103: 2936–2938.
36.
PalladiniGMilaniPFoliA, et al.
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica2014;
99: 743–750.
37.
JaccardAMoreauPLeblondV, et al.
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med2007;
357: 1083–1093.
38.
ReeceDESanchorawalaVHegenbartU, et al.
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood2009;
114: 1489–1497.
39.
SanchorawalaVPalladiniGKukretiV, et al.
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood2017;
130: 597–605.
40.
CohenADLandauHScottEC, et al.
Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis. Blood2016;
128: 645–645.
41.
SanchorawalaVWrightDGRosenzweigM, et al.
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood2007;
109: 492–496.
42.
SanchorawalaVSheltonACLoS, et al.
Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood2016;
128: 1059–1062.
43.
SanchorawalaVSarosiekSSchulmanA, et al.
Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood2020;
135: 1541–1547.
ReeceDEHegenbartUSanchorawalaV, et al.
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood2014;
124: 2498–2506.
46.
MoreauPMateosMVBerensonJR, et al.
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol2018;
19: 953–964.
47.
ManwaniRMahmoodSSachchithananthamS, et al.
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. Br J Haematol2019;
187: 638–641.
48.
SeldinDCChoufaniEBDemberLM, et al.
Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma2003;
3: 241–246.
49.
SanchorawalaVPatelJMSloanJM, et al.
Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica2013;
98: 789–792.
50.
SanchorawalaVDorosGSheltonAC.Long term outcome of patients treated on clinical trials of immunomodulatory agents for the treatment of immunoglobulin light chain (AL) amyloidosis: a pooled analysis. Am J Hematol2019;
94: E194–E196.
51.
TapanUSeldinDCFinnKT, et al.
Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood2010;
116: 5071–5072.
52.
QuallsDALewisGDSanchorawalaV, et al.
Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: a case series and review of the literature. Am J Transplant2019;
19: 3185–3190.
53.
LonialSWeissBMUsmaniSZ, et al.
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet2016;
387: 1551–1560.
54.
PalumboAChanan-KhanAWeiselK, et al.
Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med2016;
375: 754–766.
55.
DimopoulosMAOriolANahiH, et al.
Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med2016;
375: 1319–1331.
56.
ChariASuvannasankhaAFayJW, et al.
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood2017;
130: 974–981.
ComenzoRL, et al. Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone in patients with newly diagnosed amyloid light chain amyloidosis. In: 24th congress of the EHA (Abstract S875), 13–16 June 2019, Amsterdam, the Netherlands.
59.
Sanofi-Aventis U.S. LLC. Sarclisa (isatuximab-irfc) (package insert).
Bridgewater, NJ:
Sanofi-Aventis U.S. LLC, 2020.
LonialSDimopoulosMPalumboA, et al.
Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med2015;
373: 621–631.
62.
DimopoulosMADytfeldDGrosickiS, et al.
Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med2018;
379: 1811–1822.
63.
IqbalSMSteckleinKSarowJ, et al.
Elotuzumab in combination with lenalidomide and dexamethasone for treatment-resistant immunoglobulin light chain amyloidosis with multiple myeloma. Clin Lymphoma Myeloma Leuk2019;
19: e33–e36.
64.
Abbvie Inc. Venclexta (venetoclax) (package insert).
San Francisco, CA:
Abbvie Inc., 2019.
65.
SlompAPeperzakV.Role and regulation of pro-survival BCL-2 proteins in multiple myeloma. Front Oncol2018;
8: 533.
66.
KumarSKaufmanJLGasparettoC, et al.
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood2017;
130: 2401–2409.
67.
MuchtarEDispenzieriAKumarSK, et al.
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia2017;
31: 1562–1569.
68.
FonsecaRBloodEAOkenMM, et al.
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood2002;
99: 3735–3741.
69.
HaymanSRBaileyRJJalalSM, et al.
Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood2001;
98: 2266–2268.
70.
LeungNThomeSDDispenzieriA.Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone. Haematologica2018;
103: e135–e137.
71.
Le BrasFDupuisJLemonnierF, et al.
Venetoclax induces sustained complete responses in refractory/relapsed patients with cardiac AL amyloidosis. J Clin Oncol2019;
37: e19538.
72.
SidiqiMHAl SalehASLeungN, et al.
Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer J2020;
10: 55.
73.
GertzMALandauHComenzoRL, et al.
First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol2016;
34: 1097–1103.
74.
MateosMVBladéJLaroccaA, et al.
Melflufen therapy for relapsed refractory multiple myeloma (RRMM) patients refractory to daratumumab and/or pomalidomide: a report on early efficacy. Blood2017;
130: 1841.
75.
RichardsonPGBringhenSVoorheesP, et al.
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12. M1): a multicentre, international, open-label, phase 1-2 study. Lancet Haematol2020;
7: e395–e407.
76.
FlanaganKMajumderMMKumariR, et al.
In vitro and inVivo activity of melflufen in amyloidosis. Blood2019;
134: 3100–3100.
77.
GriffithsBEHughesPDowdleR, et al.
Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine. Thorax1982;
37: 711–712.
78.
PollakAFalkRH.Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest1993;
104: 618–620.
79.
GertzMASkinnerMConnorsLH, et al.
Selective binding of nifedipine to amyloid fibrils. Am J Cardiol1985;
55: 1646.
